Shares of Annexon, Inc. (NASDAQ:ANNX – Get Free Report) have received a consensus recommendation of “Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year is $15.33.
A number of brokerages have issued reports on ANNX. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research note on Wednesday, June 5th. JPMorgan Chase & Co. boosted their target price on shares of Annexon from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Monday, April 1st. Wells Fargo & Company cut their price target on shares of Annexon from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 15th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Annexon in a research note on Tuesday, June 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Annexon in a research report on Tuesday, June 4th.
View Our Latest Analysis on ANNX
Hedge Funds Weigh In On Annexon
Annexon Stock Performance
Shares of ANNX opened at $5.36 on Tuesday. Annexon has a 1 year low of $1.57 and a 1 year high of $8.40. The company’s 50 day simple moving average is $5.07 and its 200 day simple moving average is $4.90. The company has a market capitalization of $495.33 million, a price-to-earnings ratio of -3.65 and a beta of 1.30.
Annexon (NASDAQ:ANNX – Get Free Report) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.11. Equities analysts expect that Annexon will post -0.98 EPS for the current fiscal year.
About Annexon
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
See Also
- Five stocks we like better than Annexon
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Buffett Bails on BYD: What It Means for the Future of EV Stocks
- Trading Stocks: RSI and Why it’s Useful
- Domino’s vs. Papa John’s: Stock Showdown of Pizza Giants
- Top Stocks Investing in 5G Technology
- Williams-Sonoma Makes Stock More Accessible with a Stock Split
Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.